▼ -16.68% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Phreesia in the last 3 months. The average price target is $50.00, with a high forecast of $70.00 and a low forecast of $30.00. The average price target represents a -16.68% upside from the last price of $60.01.
The current consensus among 12 contributing investment analysts is to buy stock in Phreesia.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. It deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Stations that are on-site kiosks. The company's Phreesia Platform also provides a registration solution to automate patient self-registration; patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; clinical support solution that collects clinical intake and PRO data for approximately 25 specialties; appointments solution for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and life sciences, pharmaceutical, medical device, and biotechnology companies. Phreesia, Inc. has a strategic alliance agreement with Allscripts Healthcare, LLC. The company was founded in 2005 and is headquartered in New York, New York.